Companies › LucasBio
1 active drug program in 2 registered trials: 2 Phase 1; Infectious disease; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LB-DTK-COV19 allogeneic SARS-CoV-2-specific T cell therapy | – | Phase 1 | COVID-19; BKV Infection | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07709637 | LB-DTK-COV19 | Phase 1 | COVID-19 | Infectious disease | Oct 2026 |
| NCT07670468 | LB-DTK-COV19 | Phase 1 | BKV Infection | Infectious disease | Jun 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.